Objectives: For fluoroquinolones, the area under the free plasma concentration-time curve divided by the MIC (fAUC/MIC) best predicts bacterial killing in mice and outcomes in patients. However, it is unknown whether the shape of the antibiotic concentration profile affects resistance emergence. Our objective was to compare killing and resistance between ciprofloxacin concentration profiles with different shapes at the same fAUC/MIC and identify the durations of ciprofloxacin exposure that minimize resistance emergence.
Introduction
Pseudomonas aeruginosa and other Gram-negative pathogens are causing a global health crisis that is exacerbated by a severe shortage of effective antibiotics.
1 -3 P. aeruginosa causes lifethreatening infections in hospitalized patients and has an exceptional potential to become resistant during antibiotic therapy. 4 -6 The most important resistance mechanisms for fluoroquinolones in P. aeruginosa include Mex efflux pumps 7, 8 and target site mutations of gyrA and parC. 9 Over the last few decades, extensive pharmacokinetic/ pharmacodynamic (PK/PD) studies on fluoroquinolones have shown that the clinical success in patients and the bacterial killing at 24 h in mice are best predicted by the area under the free plasma concentration -time curve divided by the MIC (fAUC/ MIC). 10 -14 Forrest et al. 15 showed that a ciprofloxacin AUC/MIC .125 (equivalent to an fAUC/MIC of 87.5) is correlated with clinical success in acutely ill patients with bacterial infections, while at lower ratios the probability of clinical success was significantly decreased. However, this fAUC/MIC target was often not reached for strains with MICs of ≥1 mg/L. 16 Dose fractionation studies are commonly performed to identify the PK/PD index that best predicts bacterial killing in mice and dynamic in vitro models. These studies divide a range of daily doses into one or multiple dose(s) using different dosing intervals. In dose fractionation studies, dosing continues throughout the 24 h period (except for once-daily dosing) and therefore antibiotic concentrations are present throughout the entire treatment period. Thus, dose fractionation studies do not identify the durations of antibiotic exposure that lead to resistance emergence at a given fAUC/MIC.
The fAUC and the free peak concentration (fC max ) are often correlated in patients and the fC max /MIC usually also predicts bacterial killing in mice and clinical success of fluoroquinolones reasonably well. 12, 14, 17 Earlier studies suggested the need for future studies that identify whether dosage regimens with high fluoroquinolone peak concentrations better prevent clinical emergence of resistance than dosage regimens with lower peaks. 18, 19 However, it is still not known whether high fluoroquinolone concentrations applied over a short period yield more or less resistance than lower concentrations over a longer period at the same overall exposure (i.e. at the same fAUC/MIC). A few studies determined the fAUC/MIC value that is associated with prevention of resistance for fluoroquinolones in P. aeruginosa. 20 -23 However, it is unknown for fluoroquinolones which exposure durations lead to resistance at a given fAUC/MIC.
The primary objective of this study was to compare bacterial killing and resistance between ciprofloxacin concentration profiles at the same fAUC/MIC, but with different shapes, and to identify the durations of ciprofloxacin exposure that minimize resistance. Our second objective was to assess whether resistance emergence for the tested ciprofloxacin exposure profiles was dependent on efflux mechanisms. To achieve these objectives, we developed an appropriate study design based on static in vitro time -kill studies to evaluate resistance for different exposure profiles. Studies were performed at an initial inoculum of 10 6 cfu/mL, which most likely contained pre-existing resistant mutants, as well as at a low initial inoculum (10 4 cfu/mL), which most likely lacked such pre-existing mutants.
Materials and methods

Bacterial strains and media
The P. aeruginosa ATCC 27853 strain was used in all experiments. All susceptibility and time -kill studies were performed in cation-adjusted Mueller -Hinton broth (CAMHB; containing 20 -25 mg/L Ca 2+ and 10-12.5 mg/L Mg 2+ ; BD, Sparks, MD, USA). Viable counting was performed on cation-adjusted Mueller -Hinton agar (CAMHA; containing 25 mg/L Ca 2+ and 12.5 mg/L Mg 2+ ; Medium Preparation Unit, University of Melbourne, Parkville, Australia). Drug-containing agar plates were prepared using CAMHA (BD, Sparks, MD, USA) supplemented with the appropriate amount of ciprofloxacin.
Ciprofloxacin was purchased from Sigma-Aldrich (Shanghai, China) and the efflux pump inhibitor PABN from Bachem (Bubendorf, Switzerland). Antibiotic stock solutions were prepared in Milli-Q water and subsequently filter-sterilized using a 0.22 mm PVDF syringe filter (Merck Millipore, Cork, Ireland).
Time -kill experiments
Static time-kill experiments were performed to assess bacterial killing and emergence of resistance for different ciprofloxacin exposure profiles with and without PABN. Bacteria were grown on CAMHA and incubated at 358C for 20 h. Bacteria were then transferred into sterile CAMHB and incubated for 60 min in a shaking waterbath at 358C. The optical density of this bacterial suspension was measured via a spectrophotometer to appropriately dilute this suspension to achieve the targeted initial inocula in 20 mL of fresh, pre-warmed, sterile CAMHB. The diluted bacterial suspensions were incubated in a shaking waterbath at 358C for 15 min before the addition of ciprofloxacin, PABN or both.
We studied ciprofloxacin fAUC/MIC of 44 and 132 at initial inocula of 10 6 , 10 5 and 10 4 cfu/mL. A ciprofloxacin fAUC/MIC of 87.5 represents the PK/PD breakpoint for clinical and microbiological cure. 15 For garenoxacin, an fAUC/MIC of 48 yielded extensive resistance emergence and an fAUC/MIC of 190 prevented resistance of P. aeruginosa. 21 We studied an fAUC/MIC of 44 to obtain extensive resistance and of 132 to achieve extensive killing with limited resistance. An fAUC/MIC of 22 was additionally studied to account for the potentially diminished capacity of P. aeruginosa to become resistant in the presence of efflux pump inhibition. A range of fAUC/MIC from 25 to 100 is relevant for clinical ciprofloxacin dosage regimens at the highest treatable MICs for P. aeruginosa of 0.25 and 0.5 mg/L. These exposures were achieved by the appropriate ciprofloxacin concentration applied over 1, 4, 10, 16 and 24 h. Ciprofloxacin was dosed at 0 h and then rapidly removed at the respective timepoint (removal procedure described below).
For studies of ciprofloxacin in combination with 60 mg/L PABN, we decreased the ciprofloxacin concentrations according to the MIC ratio with and without the efflux pump inhibitor. Thus, lower ciprofloxacin concentrations were used to achieve the targeted fAUC/MIC. Ciprofloxacin fAUC/MIC of 22, 44 and 132 in combination with 60 mg/L PABN were studied at initial inocula of 10 6 and 10 4 cfu/mL. The ciprofloxacin exposure durations were 1, 4, 10, 16 and 24 h. All studies included a growth control and a 60 mg/L PABN control without ciprofloxacin. The concentrations and exposure durations that were studied are listed in Table 1 , both for studies without and with PABN.
Ciprofloxacin or ciprofloxacin and PABN were rapidly removed by multiple sequential centrifugation and resuspension steps. For vials with ciprofloxacin concentrations of ≥8× MIC, three sequential centrifugation and resuspension processes were used; for lower concentrations, two sequential steps were applied. The conical vials containing the bacterial cultures in broth were centrifuged at 3220 g for 10 min at 358C, the supernatant removed and the bacteria resuspended in fresh, pre-warmed, drug-free CAMHB. The overall drug dilution factor was 400-fold for two sequential centrifugation and resuspension processes and 8000-fold for three processes. This method assured that the ciprofloxacin concentrations were negligible (,0.004× MIC) after drug removal.
Viable counting
For all experimental arms, counts of viable bacteria were determined within 5 min prior to dosing and at 1, 2, 3.5 or 3.9, 6, 12, 16.5 and 24 h after dosing. Bacterial numbers were also determined 5 min prior to drug removal and 10 min after the final bacterial resuspension in fresh broth to assure minimal loss of bacteria during drug removal. All viable count samples were washed twice in sterile saline to effectively minimize antibiotic carryover. Colony counts on CAMHA were determined by manual plating of 100 mL of the undiluted or diluted bacterial suspensions in saline. This plating method yielded a limit of counting of 1.0 log 10 cfu/mL (equivalent to one colony per plate). Agar plates were incubated at 358C for 48 h.
Emergence of resistance
Mutant frequencies (MFs) were determined at 0 h (i.e. before treatment) and at 24 h to determine the abundance of resistant bacteria in the population before and after treatment. MICs were determined at 24 h by spectrophotometrically adjusting the bacterial suspensions (i.e. dilution in fresh, pre-warmed, sterile CAMHB) to an inoculum of 10 6 cfu/mL if the 6 cfu/mL at 24 h, undiluted bacterial suspensions were used for MIC testing at 24 h. Ciprofloxacin was removed from all arms before testing emergence of resistance.
Agar plates containing 3×or 5×the ciprofloxacin MIC were used for studies on ciprofloxacin monotherapy. For studies on ciprofloxacin with 60 mg/L PABN, the ciprofloxacin concentration in agar was calculated based on the lower MIC in the presence of PABN and drug plates contained 3× or 5× this lower ciprofloxacin MIC plus 60 mg/L PABN. Antibiotic-containing agar plates were incubated for 3 days and MF calculated as the difference between the log 10 cfu/mL on antibiotic-containing agar plates and the log 10 cfu/mL on drug-free plates at the same observation time.
Some of the viable counts at 24 h were too low to enable quantifying colonies on antibiotic-containing agar plates. These arms still provided information on the upper limit of the log 10 MF (such as log 10 MF of 26 or less). To include these data in the summary statistics, we used the following reporting rules. If the calculated MF was not quantifiable, but the upper limit was within 1.1 log 10 of the MF for the growth control, we assumed the MF was unchanged and used the value of the growth control. If the MF was not quantifiable and the upper limit was .1.1 log 10 higher than the MF for the growth control, the MF of this arm was reported as missing.
Results
The MIC of ciprofloxacin for P. aeruginosa ATCC 27853 was 0.25 mg/L. The log 10 mutation frequency before treatment was 26.2 on 3× MIC ciprofloxacin plates and 27.1 on 5× MIC ciprofloxacin plates. As expected, the extent of killing of P. aeruginosa increased with the ciprofloxacin exposure (fAUC/MIC). Ciprofloxacin without PABN at fAUC/MIC of 44 and 132 yielded 2 to .5 log 10 killing (Figure 1 ). At the fAUC/MIC of 44, initial killing was noticeably slower for the 16 and 24 h durations of exposure than for the shorter durations. Initial killing was rapid for all durations of exposure at the fAUC/MIC of 132 with minimum viable counts occurring within the first 4 h.
Considerable regrowth at 24 h was observed for the vast majority of ciprofloxacin profiles, in particular at the 10 5 and 10 6 cfu/mL inocula. Complete killing with no regrowth was observed for the 4 h duration of exposure at the fAUC/MIC of 132 for the 10 4 cfu/mL inoculum. Based on our MF results, the 10 4 cfu/mL inoculum had a probability of 1.2% to harbour at least one pre-existing mutant cell resistant at 5× MIC; the probability was 10% at 3× MIC. In contrast, the 10 6 cfu/mL inoculum had a probability .99.99% to contain at least one pre-existing resistant mutant at 3× MIC and a probability of 80% to contain a resistant mutant at 5× MIC. Overall regrowth was slower and viable counts at 24 h tended to be lower for the 24 h duration of exposure compared with the shorter durations ( Figure 1) .
The extensive regrowth at 24 h for almost all viable count profiles posed the important question of whether these bacteria were resistant to ciprofloxacin. Interestingly, for the 24 h ciprofloxacin exposure, the MF on 3× MIC plates was 6.1 log 10 (at the fAUC/MIC of 44) and 5.6 log 10 (at the fAUC/MIC of 132) higher than the MF of the growth control at 24 h (Figure 2 ). Likewise, a 5.9 log 10 (at the fAUC/MIC of 44) and 7.3 log 10 (at the fAUC/MIC of 132) higher MF on 5× MIC plates was observed. This trend was clearly present for both the 10 6 and 10 5 cfu/mL inocula. Ciprofloxacin over a 16 h exposure duration at the fAUC/MIC of 44 yielded up to 6.5 log 10 increased MF on 3× and 5× MIC plates, whereas the MF was increased by up to 2.6 log 10 for the fAUC/MIC of 132 at the 10 6 cfu/mL inoculum. Emergence of resistance, however, did not occur or was substantially less for the shorter durations of ciprofloxacin exposure (1, 4 and 10 h). The MF for these durations of exposure was comparable to the MF of the growth control at 24 h (only up to 1.9 log 10 higher) for all studied inocula on 3× and 5× MIC plates ( Figure 2) .
The higher MF correlated well with the increased MICs at 24 h ( Table 2 ). The MICs remained relatively unchanged for 1 -10 h durations of exposure, whereas the MICs increased up to 8-fold at the 10 6 and 10 5 cfu/mL inocula for the 16 and 24 h durations of exposure ( Table 2 ). Emergence of resistance at the 10 4 cfu/mL inoculum was much less compared with the 10 6 and 10 5 cfu/mL inocula ( Figure 2 and Table 2 ).
To explore whether efflux was the primary cause for emergence of resistance, we carried out time -kill experiments in the presence of 60 mg/L PABN (Figure 3) . The ciprofloxacin MIC was 0.031 mg/L in the presence of 60 mg/L PABN. Thus, 8-fold lower ciprofloxacin concentrations were used to account for the lower MIC in the presence of PABN. The log 10 mutation frequency before treatment was 25.4 on 3× MIC ciprofloxacin with PABN plates and was 28.2 on 5× MIC ciprofloxacin with Rees et al. , 10 5 and 10 4 cfu/mL were studied for the fAUC/MIC of 44 and inocula of 10 6 and 10 4 cfu/mL for the fAUC/MIC of 132. The fAUC/MIC of 132 yielded eradication for the 4 h exposure duration at the 10 4 cfu/mL inoculum and thus no MF could be determined. The 16 h duration of exposure was not studied at the 10 4 cfu/mL inoculum. The MF for the 24 h exposure at the 10 4 cfu/mL inoculum was arbitrarily drawn at 29.5 log 10 (i.e. below the limit of quantification); these two experimental arms had ,10 3.3 cfu/mL for the total population at 24 h and no colonies grew on antibiotic-containing agar plates.
High concentrations over short times prevent resistance 821 JAC PABN plates. Viable count profiles for 60 mg/L PABN largely paralleled the growth control. In the presence of PABN, all experimental arms achieved .5 log 10 killing at the ciprofloxacin fAUC/MIC of 132. At the fAUC/MIC of 22 and 44, the maximum extent of killing was larger and minimum viable counts occurred earlier for the shorter compared with the longer durations of exposure (Figure 3) . Even in the presence of 60 mg/L PABN, ciprofloxacin could not eradicate P. aeruginosa. Regrowth was limited or absent for the 24 h duration of exposure at all studied fAUC/MIC, but regrowth occurred for the shorter durations of exposure.
For ciprofloxacin combined with 60 mg/L PABN, 10 and 16 h durations of exposure led, in general, to considerably increased MF at 24 h on 3× MIC plates compared with the MF of the growth control at 24 h (Figure 4 ). Resistance emergence was absent or much less for the 1 and 4 h durations of exposure. Viable counts for the 24 h duration of exposure were low at 24 h and the MF was usually below the quantification limit for these arms. Resistance on 3× MIC plates was similar for ciprofloxacin with and without the efflux pump inhibitor ( Figures 2 and 4) ; except for the 10 h duration of exposure for the fAUC/MIC of 132 that showed an 6.4 log 10 increase in MF in the presence of PABN (Figure 4 ). However, resistance on 5× MIC plates was less in the presence of PABN compared with the absence of PABN. Emergence of resistance for the 16 and 24 h durations of exposure also occurred for an fAUC/MIC of 22, but was less pronounced at this low ciprofloxacin fAUC/MIC.
The MF corresponded with the MICs of the combination of ciprofloxacin with 60 mg/L PABN (Table 3) . MICs were relatively unchanged except for the 16 h duration of exposure, which led to a 5-to 10-fold increased MIC for fAUC/MIC of 44 or 132 at the 10 6 cfu/mL inoculum ( Table 3) . The MICs at 24 h could not 9 cfu/mL, the log 10 MF of the growth controls for 5× MIC is drawn as 29 (below the limit of quantification). For all experimental arms that had no colonies on agar plates containing 5×MIC ciprofloxacin and that had a viable count of ≥10 7.9 cfu/mL on antibiotic-free agar plates, the log 10 MF was drawn as 29. For experimental arms that showed no colonies on antibiotic-containing agar plates that had total populations of ,10 7.9 cfu/mL on antibiotic-free agar plates, the log 10 MF was arbitrarily drawn at 29.5 (below the limit of quantification). High concentrations over short times prevent resistance 823 JAC be determined for the 24 h duration of exposure for fAUC/MIC of 44 and 132, probably due to the low viable counts.
Discussion
Many PK/PD studies on fluoroquinolones have found the fAUC/MIC to be the PK/PD index that best predicts bacterial killing in mice and therapeutic success in patients. 11,13 -15 From such studies conducted during drug development, clinical dosing of fluoroquinolones is now guided by the fAUC/MIC. However, only a few studies assessed prevention of resistance to fluoroquinolones against Gram-negative pathogens. 20 -23 While the design of these studies implicitly assumed that the fAUC/MIC best predicts prevention of resistance for fluoroquinolones, it is unknown which PK/PD index is relevant for this endpoint. In fact, for rifampicin and linezolid, different PK/PD indices predict bacterial killing (fAUC/MIC) and prevention of resistance (fC max /MIC). 24, 25 In the present study, we demonstrated that emergence of resistance was more prominent (.5 log 10 ) at longer durations of exposure (16 and 24 h) than shorter durations at the same fAUC/MIC ( Figure 2 and Table 2 ). A short duration of exposure yielded more killing at 2-4 h than long durations of exposure at the same fAUC/MIC (Figure 1 ). At the 10 4 cfu/mL inoculum, no or little emergence of resistance was present and MICs were not elevated, most likely due to lack of pre-existing resistant mutants ( Figure 2 and Table 2 ). It seems possible that the high ciprofloxacin concentrations during the 1-10 h durations of exposure killed both susceptible and resistant bacteria to a comparable extent and therefore did not give rise to emergence of resistance. In contrast, the 24 h duration of exposure probably provided a growth advantage for resistant mutants. Alternatively, adaptive resistance, if present, might require durations of antibiotic exposure of .10 h to be (fully) up-regulated or adaptive resistance may revert back to baseline between 10 and 24 h. The latter two alternatives seem less likely, as efflux of levofloxacin in P. aeruginosa was extensively up-regulated within 1 h and did not revert back to baseline between 6 and 24 h, i.e. when levofloxacin concentrations were negligible due to a short half-life and a 24 h dosing interval in mice. 22 We also considered the possibility that the emergence of resistance for longer durations of ciprofloxacin exposure may have been due to induction of the SOS response. 26, 27 However, we observed considerably less emergence of resistance in the 10 4 (unlike the 10 6 ) cfu/mL inoculum at the same fAUC/MIC, which suggests resistance was at least in part caused by pre-existing resistant mutants. Furthermore, antibiotic treatment has been proposed to cause oxidative stress, which, when this stress is only small, allows beneficial mutations and therefore emergence of resistance to occur instead of bacterial killing. 28 However, as discussed above, most of the resistance emergence observed in the present study may probably have been due to pre-existing resistant mutants. Ultimately, molecular studies combined with a full mechanism-based modelling analysis would be highly valuable to elucidate these mechanistic details.
We explored the role of efflux in the observed rapid and extensive emergence of resistance. In the presence of the broadspectrum efflux pump inhibitor PABN, which inhibits the most relevant efflux pumps for fluoroquinolones (MexAB, MexCD and MexEF), 7 considerable emergence of resistance occurred for fAUC/MIC of 44 and 132 for the 16 h duration of exposure ( Figure 4 and Table 3 ). Emergence of resistance was less pronounced at the fAUC/MIC of 22, probably because this drug exposure did not provide a sufficient growth advantage for less susceptible bacteria, in agreement with the inverted-U principle 20, 21 and the general concept of the mutant selection window. 29 As emergence of resistance on 5× MIC plates in the presence of PABN was considerably less (Figure 4 ) than in the absence of PABN (Figure 2 ), efflux played a role in the development of high-level resistance.
The extensive contribution of efflux pumps to fluoroquinolone resistance was studied in detail in a 48 h mouse infection model at a high bacterial inoculum; an fAUC/MIC of 110 for levofloxacin (equivalent to a total drug AUC/MIC of 157) prevented amplification of resistant mutants whereas an fAUC/MIC of 37 led to amplification of resistant mutants. 22 Two hollow fibre in vitro infection model studies determined the fAUC/MIC of garenoxacin that prevented resistance; 20, 21 for P. aeruginosa, an fAUC/MIC of 190 prevented amplification of pre-existing resistant mutants at 48 h. 21 Another hollow fibre study found extensive emergence of resistance to ciprofloxacin by 48-72 h using a ciprofloxacin fAUC/MIC of 180 against three P. aeruginosa strains. 23 The studies mentioned above 20 -23 assessed emergence of resistance for different dose levels and thus for different fAUC/MIC. These studies neither varied the fluoroquinolone half-life nor the dosing interval and therefore kept the shape of the antibiotic concentration -time profile constant.
An earlier dose fractionation study in the hollow fibre model with ciprofloxacin against two P. aeruginosa isolates found extensive resistance emergence for 400 mg of ciprofloxacin dosed every 8 h and 600 mg every 12 h (equivalent to an fAUC/MIC of 60). 19 Resistance emergence at 24 h was less extensive for one isolate and absent for a second P. aeruginosa isolate for 1200 mg of ciprofloxacin every 24 h, but this regimen was subject to regrowth of mostly susceptible P. aeruginosa at 24 h. 19 Another in vitro study gave the same daily enoxacin dose (equivalent to an fAUC/MIC of 50) every 12 or 24 h and found more killing for dosing every 24 h. However, extensive P. aeruginosa resistance occurred at 12 -24 h for both regimens. 30 These dose fractionation studies 19, 30 had high or low fluoroquinolone concentrations present throughout the entire treatment period. Therefore, the durations of fluoroquinolone exposure that lead to resistance have not been assessed previously. 19 -23,30 The present study systematically explored whether the shape of the ciprofloxacin concentration -time profile affects bacterial killing and resistance emergence. We developed an appropriate in vitro study design that delivered the same fAUC/MIC by varying the duration of exposure and concentration of ciprofloxacin (and the efflux pump inhibitor where applicable) accordingly. Most available studies on emergence of fluoroquinolone resistance in dynamic in vitro or animal models were performed at high inocula that contained pre-existing resistant mutants. 20 -22 We extended these studies by assessing a low inoculum (10 4 cfu/mL) in duplicate that most likely (probability ≥90%) lacked pre-existing resistant mutants.
Our study was designed to achieve the objectives of this work; a potential limitation is the use of static antibiotic concentrations. Therefore, future studies in dynamic in vitro and animal infection models are warranted to further confirm that short durations of exposure provide killing with no or limited resistance. Our study lacked the effect of the immune system and used standard, nutrient-rich broth medium. These factors probably resulted in more rapid (re)growth of bacteria compared with an in vivo infection, in agreement with the relatively slow regrowth of P. aeruginosa in mice. 22 In summary, we found that delivering the same fAUC/MIC over short durations of exposure (i.e. 1, 4 or 10 h) achieved more rapid killing with no or very limited emergence of resistance, whereas longer durations of exposure over 16 and 24 h led to a dramatic (5 log 10 ) increase in the concentration of resistant bacteria. Therefore, the shape of the concentration-time profile had a pronounced effect on prevention of resistance emergence. Pre-existing resistant mutants probably caused emergence of resistance. Efflux was important for the development of high-level resistance (at 5× MIC), but was not required for the development of low-level resistance on 3×MIC plates. Regrowth of P. aeruginosa was extensive for most regimens with durations of exposure of up to 16 h, indicating that the post-antibiotic effect of ciprofloxacin was short. 31 Therefore, clinical ciprofloxacin regimens with highintensity, short-exposure durations may provide extensive and rapid bacterial killing with no or limited resistance. They would be expected to be best used as part of a combination regimen with a second antibiotic that prevents regrowth of ciprofloxacinsusceptible bacteria. Studies in dynamic in vitro and animal infection models are warranted to optimally translate our results to future studies in patients. The present study highlights the potential to greatly minimize emergence of resistance by innovative fluoroquinolone dosage regimens with an optimized shape of the plasma concentration -time profiles.
